Test Code PKUBS Phenylalanine and Tyrosine, Blood Spot
Reporting Name
Phenylalanine and Tyrosine, BSUseful For
Monitoring effectiveness of therapy in patients with hyperphenylalaninemia
This test is not sufficient for follow-up for abnormal newborn screening results or for establishing a diagnosis of a specific cause of hyperphenylalaninemia
Method Name
Liquid Chromatography Tandem Mass Spectrometry (LC-MS/MS)
Performing Laboratory
Mayo Clinic Laboratories in RochesterSpecimen Type
Whole bloodOrdering Guidance
For follow-up of an abnormal newborn screen for potential phenylketonuria, order PKU / Phenylalanine and Tyrosine, Plasma.
Necessary Information
Patient's age is required.
Specimen Required
Submit only 1 of the following specimen types:
Preferred:
Specimen Type: Blood spot
Supplies: Card-Blood Spot Collection (Filter Paper) (T493)
Container/Tube:
Preferred: Blood Spot Collection Card
Acceptable: Whatman Protein Saver 903 Paper, PerkinElmer 226 filter paper, Munktell filter paper, or blood collected in tubes containing EDTA and dried on filter paper.
Specimen Volume: 2 Blood spots
Collection Instructions:
1. An alternative blood collection option for a patient older than 1 year is a fingerstick. For detailed instructions, see How to Collect Dried Blood Spot Samples.
3. Let blood dry on filter paper at room temperature in a horizontal position for a minimum of 3hours.
4. Do not expose specimen to heat or direct sunlight.
5. Do not stack wet specimens.
6. Keep specimen dry.
Specimen Stability Information: Ambient (preferred) 90 days/Refrigerated 90 days/Frozen 90 days
Additional Information:
1. For collection instructions, see Blood Spot Collection Instructions
2. For collection instructions in Spanish, see Blood Spot Collection Card-Spanish Instructions (T777
3. For collection instructions in Chinese, see Blood Spot Collection Card-Chinese Instructions (T800)
Acceptable:
Specimen Type: Whole blood
Container/Tube: Lavender top (EDTA)
Specimen Volume: 2 mL
Collection Instructions: Send whole blood specimen in original tube. Do not aliquot.
Specimen Stability Information: Refrigerate 6 days
Specimen Minimum Volume
Blood spots: 1
Whole blood: 0.5 mL
Specimen Stability Information
Specimen Type | Temperature | Time | Special Container |
---|---|---|---|
Whole blood | Varies |
Reject Due To
Blood spot specimen that shows serum rings or has multiple layers | Reject |
Insufficient specimen | Reject |
Unapproved filter papers | Reject |
Special Instructions
Reference Values
PHENYLALANINE
27-107 nmol/mL
TYROSINE
<4 weeks: 40-280 nmol/mL
≥4 weeks: 25-150 nmol/mL
Day(s) Performed
Monday through Friday
CPT Code Information
84030
84510
82542 (if appropriate for government payers)
LOINC Code Information
Test ID | Test Order Name | Order LOINC Value |
---|---|---|
PKUBS | Phenylalanine and Tyrosine, BS | 79621-9 |
Result ID | Test Result Name | Result LOINC Value |
---|---|---|
92405 | Phenylalanine, BS | 29573-3 |
92406 | Tyrosine, BS | 35571-9 |
92407 | Reviewed By | 18771-6 |
Secondary ID
65593Clinical Information
Phenylketonuria (PKU) is the most frequent inherited disorder of amino acid metabolism (occurring in about 1:10,000-1:15,000 births) and was the first successfully treated inborn error of metabolism. It is inherited in an autosomal recessive manner and is caused by a defect in the enzyme phenylalanine hydroxylase (PAH), which converts the essential amino acid phenylalanine to tyrosine. Deficiency of PAH results in decreased levels of tyrosine and an accumulation of phenylalanine in blood and tissues. Untreated, PKU leads to severe brain damage with intellectual impairment, behavior abnormalities, seizures, and spasticity. The level of enzyme activity differentiates classic PKU (PAH activity <1%) from other milder forms; however, all are characterized by increased levels of phenylalanine (hyperphenylalaninemia). Treatment includes the early introduction of a diet low in phenylalanine. Some patients may also benefit from adjuvant tetrahydrobiopterin (BH4) supplementation (a cofactor for PAH), or enzyme substitution therapy.
BH4 is a cofactor of not only PAH but also of the tyrosine and tryptophan hydroxylases. Approximately 2% of patients with hyperphenylalaninemia have a deficiency of BH4, which causes a secondary deficit of the neurotransmitters dopamine and serotonin. There are 4 autosomal-recessive disorders associated with BH4 deficiency plus hyperphenylalaninemia: guanosine triphosphate cyclohydrolase deficiency, 6-pyruvoyl tetrahydropterin synthase deficiency, dihydropteridine reductase deficiency, and pterin-4 alpha carbinolamine dehydratase (PCD) deficiency. This group of disorders, except for PCD, is characterized by progressive dystonia, truncal hypotonia, extremity hypertonia, seizures, and intellectual disability though milder presentations exist. PCD has no symptoms other than transient alterations in tone. Treatment may include administration of BH4, L-dopa (and carbidopa) 5-hydroxytryptophan supplements, and a low phenylalanine diet.
Tyrosine is a nonessential amino acid that is derived from dietary sources, the hydroxylation of phenylalanine, or protein breakdown. Primary (PKU) and secondary (defects of BH4 metabolism) hyperphenylalaninemia can cause abnormally low levels of tyrosine. Measurement of the phenylalanine:tyrosine ratio is helpful in monitoring appropriate dietary intake.
Interpretation
The quantitative results of phenylalanine and tyrosine with age-dependent reference values are reported without added interpretation. When applicable, reports of abnormal results may contain an interpretation based on available clinical information.
A phenylalanine:tyrosine ratio higher than 3 is considered abnormal.
Cautions
No significant cautionary statements
Clinical Reference
1. Mitchell GA, Grompe M, Lambert M, Tanguay RM. Hypertyrosinemia. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA. eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw Hill; 2019. Accessed December 26 2023. Available at https://ommbid.mhmedical.com/content.aspx?bookid=2709§ionid=225082825
2. Donlon J, Sarkissian C, Levy H, Scriver CR: Hyperphenylalaninemia: Phenylalanine hydroxylase deficiency. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, eds. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw-Hill; 2019. Accessed December 26, 2023. Available at https://ommbid.mhmedical.com/content.aspx?bookid=2709§ionid=225081923
3. Regier DS, Greene CL. Phenylalanine hydroxylase deficiency. In: Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews [Internet]. University of Washington, Seattle; 2000. Updated January 5, 2017. Accessed December 26, 2023. Available at www.ncbi.nlm.nih.gov/books/NBK1504/
Method Description
A 3-mm disk is punched out of the dried blood spot onto a 96-well plate. The amino acids are extracted by the addition of acetonitrile and known concentrations of isotopically labeled amino acids as internal standards. The extract is moved to another 96-well plate, dried under a stream of nitrogen, and derivatized by the addition of n-butanol hydrochloric acid. Analytes are measured by liquid chromatography tandem mass spectrometry. The concentrations of the phenylalanine and tyrosine are established by computerized comparison of ion intensities of these analytes to that of the respective internal standards.(Unpublished Mayo method)
Report Available
3 to 5 daysSpecimen Retention Time
1 yearTest Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.Forms
If not ordering electronically, complete, print, and send a Biochemical Genetics Test Request (T798) with the specimen.